MUNI
MED

Příloha č. 3: Publikace vztahující se k tématu disertace

Příjmení, jméno, titul, učo:	Kubešová Blanka, Mgr.Bc., 132703

Souhrn

Publikace		Počet	IF/Q-WOS
Jimp	Prvoautorské	1	1.: 9,944/Q1
	Spoluautorské	5	1.: 9,994/Q1 2.: 2,511/Q1 3.: 11,702/Q1 4.: 11,847/Q1 5.: 5,868/Q1
Další	Knihy		
	Kapitoly v knize		
	Příspěvky ve sborníku		7
	Jiné (patenty...)		1

Detailní přehled publikační aktivity
Originální práce s IF[1]

A. Prvoautorské

1. Bibliografický záznam práce[2]

Kubesova B, Pavlova S, Malcikova J, Kabathova J, Radova L, Tom N, Tichy B, Plevova K, Kantorova B, Fiedorova K, Slavikova M, Bystry V, Kissova J, Gisslinger B, Gisslinger H, Penka M, Mayer J, Kralovics R, Pospisilova S, Doubek M. Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status. Leukemia. 2018 Feb;32(2):450-461. doi: 10.1038/leu.2017.230. Epub 2017 Jul 24. PubMed PMID: 28744014; PubMed Central PMCID: PMC5808067.

IF[3]	Q WOS	WOS kategorie
9,944	Q1	HEMATOLOGY

Citace (bibliografické záznamy citací)[4]

1. Orlova A, Wingelhofer B, Neubauer HA, Maurer B, Berger-Becvar A, Keserű GM, Gunning PT, Valent P, Moriggl R. Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas. Expert Opin Ther Targets. 2018 Jan;22(1):45-57. doi: 10.1080/14728222.2018.1406924. Epub 2017 Nov 24. Review. PubMed PMID: 29148847; PubMed Central PMCID: PMC5743003.
2. Venton G, Courtier F, Charbonnier A, D'incan E, Saillard C, Mohty B, Mozziconacci MJ, Birnbaum D, Murati A, Vey N, Rey J. Impact of gene mutations on

[1] U publikací s IF (Impakt faktor) uvádějte i kategorii dle WOS a Q WOS (Impakt faktor kvartil), příklad: IF=1,167; GENETICS & HEREDITY Q4 (v případě více kategorií, uveďte kategorii s nejvyšším příslušným kvartilem).
[2] S ohledem na provádění následných kontrol dle nařízení/směrnic LF MU uvádějte při citování článků v případě více tvůrců všechny autory, NEPOUŽÍVEJTE zkratku „et al.“, „aj.“ (nebo ekvivalent v řeči, ve které je článek napsán).
[3] Uvádějte IF v roce publikování. Pokud je publikace zatím pouze přijata k tisku, uvádějte aktuální IF časopisu. Po schválení oborovou radou je možné uvádět i publikace před zahájením Ph.D. studia.
[4] Uvádějte jen nejvýznamnější citace. Je možné uvést i více citací než tři. Neuvádějí se autocitace, za autocitace se považuje i citace spoluautorů.

treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms. Am J Hematol. 2018 Mar;93(3):330-338. doi: 10.1002/ajh.24973. Epub 2017 Dec 6. PubMed PMID: 29148089.
3. Cheng Z, Zhou L, Hu K, Dai Y, Pang Y, Zhao H, Wu S, Qin T, Han Y, Hu N, Chen L, Wang C, Zhang Y, Wu D, Ke X, Shi J, Fu L. Prognostic significance of microRNA-99a in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2018 Sep;53(9):1089-1095. doi: 10.1038/s41409-018-0146-0. Epub 2018 Mar 7. PubMed PMID: 29515250.
4. Greenfield G, McPherson S, Mills K, McMullin MF. The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms. J Transl Med. 2018 Dec 17;16(1):360. doi: 10.1186/s12967-018-1729-7. Review. PubMed PMID: 30558676; PubMed Central PMCID: PMC6296062.
5. Marcellino BK, Hoffman R, Tripodi J, Lu M, Kosiorek H, Mascarenhas J, Rampal RK, Dueck A, Najfeld V. Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53. Blood Adv. 2018 Dec 26;2(24):3581-3589. doi: 10.1182/bloodadvances.2018024018. PubMed PMID: 30563882;
PubMed Central PMCID: PMC6306879.
6. Wanquet A, Courtier F, Guille A, Carbuccia N, Garnier S, Adélaide J, Gelsi-Boyer V, Mozziconacci MJ, Rey J, Vey N, Birnbaum D, Murati A. Mutation patterns in essential thrombocythemia, polycythemia vera and secondary myelofibrosis. Leuk Lymphoma. 2019 May;60(5):1289-1293. doi: 10.1080/10428194.2018.1522437. Epub 2019 Jan 2. PubMed PMID: 30601073.
7. Mascarenhas J, Lu M, Kosiorek H, Virtgaym E, Xia L, Sandy L, Mesa R, Petersen B, Farnoud N, Najfeld V, Rampal R, Dueck A, Hoffman R. Oral idasanutlin in patients with polycythemia vera. Blood. 2019 Aug 8;134(6):525-533. doi: 10.1182/blood.2018893545. Epub 2019 Jun 5. PubMed PMID: 31167802; PubMed Central PMCID: PMC6688433.
8. Fu L, Qi J, Gao X, Zhang N, Zhang H, Wang R, Xu L, Yao Y, Niu M, Xu K. High expression of miR-338 is associated with poor prognosis in acute myeloid leukemia undergoing chemotherapy. J Cell Physiol. 2019 Nov;234(11):20704-20712. doi: 10.1002/jcp.28676. Epub 2019 Apr 17. PubMed PMID: 30997674.

B. Spoluautorské

1. Bibliografický záznam práce
Czech J, Cordua S, Weinbergerova B, Baumeister J, Crepcia A, Han L, Maié T, Costa IG, Denecke B, Maurer A, Schubert C, Feldberg K, Gezer D, Brümmendorf TH, Müller-Newen G, Mayer J, Racil Z, **Kubesova B**, Knudsen T, Sørensen AL, Holmström M, Kjær L, Skov V, Larsen TS, Hasselbalch HC, Chatain N, Koschmieder S. JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation. Leukemia. 2019 Apr;33(4):995-1010. doi: 10.1038/s41375-018-0295-6. Epub 2018 Nov 23. PubMed PMID: 30470838.

IF	Q WOS	WOS kategorie
9,994	Q1	HEMATOLOGY

Citace (bibliografické záznamy citací)

1. Bose P, Verstovsek S. Updates in the management of polycythemia vera and essential thrombocythemia. Ther Adv Hematol. 2019 Aug 30;10:2040620719870052. doi: 10.1177/2040620719870052. eCollection 2019. Review. PubMed PMID: 31516686; PubMed Central PMCID: PMC6719465.
2. Desterro J, McLornan DP, Curto Garcia N, O'Sullivan J, Alimam S, Keohane C, Woodley C, Francis Y, Kordasti S, Radia DH, Harrison CN. Essential

thrombocythaemia treated with recombinant interferon: 'real world' United Kingdom referral centre experience. Br J Haematol. 2019 Aug;186(4):561-564. doi: 10.1111/bjh.15968. Epub 2019 May 15. PubMed PMID: 31090926.

3. Cottin L, Riou J, Orvain C, Ianotto JC, Boyer F, Renard M, Truchan-Graczyk M, Murati A, Jouanneau-Courville R, Allangba O, Mansier O, Burroni B, Rousselet MC, Quintin-Roué I, Martin A, Sadot-Lebouvier S, Delneste Y, Chrétien JM, Hunault-Berger M, Blanchet O, Lippert E, Ugo V, Luque Paz D. Sequential mutational evaluation of CALR -mutated myeloproliferative neoplasms with thrombocytosis reveals an association between CALR allele burden evolution and disease progression. Br J Haematol. 2019 Nov 11. doi: 10.1111/bjh.16276. [Epub ahead of print] PubMed PMID: 31710700.

2. Bibliografický záznam práce
Tom N, Tom O, Malcikova J, Pavlova S, **Kubesova B**, Rausch T, Kolarik M, Benes V, Bystry V, Pospisilova S. ToTem: a tool for variant calling pipeline optimization. BMC Bioinformatics. 2018 Jun 26;19(1):243. doi: 10.1186/s12859-018-2227-x. PubMed PMID: 29940847; PubMed Central PMCID: PMC6020218.

IF	Q WOS	WOS kategorie
2,511	Q1	MATHEMATICAL & COMPUTATIONAL BIOLOGY

3. Bibliografický záznam práce
Nivarthi H, Chen D, Cleary C, **Kubesova B**, Jäger R, Bogner E, Marty C, Pecquet C, Vainchenker W, Constantinescu SN, Kralovics R. Thrombopoietin receptor is required for the oncogenic function of CALR mutants. Leukemia. 2016 Aug;30(8):1759-63. doi: 10.1038/leu.2016.32. Epub 2016 Feb 17. PubMed PMID: 26883579; PubMed Central PMCID: PMC4980558.

IF	Q WOS	WOS kategorie
11,702	Q1	HAMATOLOGY

Citace (bibliografické záznamy citací)

1. Bose P, Verstovsek S. JAK2 inhibitors for myeloproliferative neoplasms: what is next? Blood. 2017 Jul 13;130(2):115-125. doi: 10.1182/blood-2017-04-742288. Epub 2017 May 12. Review. PubMed PMID: 28500170; PubMed Central PMCID: PMC5510786.
2. Han L, Schubert C, Köhler J, Schemionek M, Isfort S, Brümmendorf TH, Koschmieder S, Chatain N. Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion. J Hematol Oncol. 2016 May 13;9(1):45. doi: 10.1186/s13045-016-0275-0. PubMed PMID: 27177927; PubMed Central PMCID: PMC4894373.
3. Imai M, Araki M, Komatsu N. Somatic mutations of calreticulin in myeloproliferative neoplasms. Int J Hematol. 2017 Jun;105(6):743-747. doi: 10.1007/s12185-017-2246-9. Epub 2017 May 3. Review. PubMed PMID: 28470469.

4. Bibliografický záznam práce
Milosevic Feenstra JD, Nivarthi H, Gisslinger H, Leroy E, Rumi E, Chachoua I, Bagienski K, **Kubesova B**, Pietra D, Gisslinger B, Milanesi C, Jäger R, Chen D, Berg T, Schalling M, Schuster M, Bock C, Constantinescu SN, Cazzola M, Kralovics R. Whole-exome sequencing identifies novel MPL and JAK2 mutations in

triple-negative myeloproliferative neoplasms. Blood. 2016 Jan 21;127(3):325-32. doi: 10.1182/blood-2015-07-661835. Epub 2015 Sep 30. PubMed PMID: 26423830; PubMed Central PMCID: PMC4752213.

IF	Q WOS	WOS kategorie
11,847	Q1	HEMATOLOGY

Citace (bibliografické záznamy citací)

1. Cabagnols X, Favale F, Pasquier F, Messaoudi K, Defour JP, Ianotto JC, Marzac C, Le Couédic JP, Droin N, Chachoua I, Favier R, Diop MK, Ugo V, Casadevall N, Debili N, Raslova H, Bellanné-Chantelot C, Constantinescu SN, Bluteau O, Plo I, Vainchenker W. Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. Blood. 2016 Jan 21;127(3):333-42. doi: 10.1182/blood-2015-07-661983. Epub 2015 Oct 8. PubMed PMID: 26450985.
2. Tefferi A. Myeloproliferative neoplasms: A decade of discoveries and treatment advances. Am J Hematol. 2016 Jan;91(1):50-8. doi: 10.1002/ajh.24221. Review. PubMed PMID: 26492355.
3. Tefferi A, Lasho TL, Finke CM, Elala Y, Hanson CA, Ketterling RP, Gangat N, Pardanani A. Targeted deep sequencing in primary myelofibrosis. Blood Adv. 2016 Nov 30;1(2):105-111. doi: 10.1182/bloodadvances.2016000208. eCollection 2016 Dec 13. PubMed PMID: 29296803; PubMed Central PMCID: PMC5737166.

5. Bibliografický záznam práce
Navrkalova V, Sebejova L, Zemanova J, Kminkova J, **Kubesova B**, Malcikova J, Mraz M, Smardova J, Pavlova S, Doubek M, Brychtova Y, Potesil D, Nemethova V, Mayer J, Pospisilova S, Trbusek M. ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin. Haematologica. 2013 Jul;98(7):1124-31. doi: 10.3324/haematol.2012.081620. Epub 2013 Apr 12. PubMed PMID: 23585524; PubMed Central PMCID: PMC3696617.

IF	Q WOS	WOS kategorie
5,868	Q1	HEMATOLOGY

Citace (bibliografické záznamy citací)

1. Choi M, Kipps T, Kurzrock R. ATM Mutations in Cancer: Therapeutic Implications. Mol Cancer Ther. 2016 Aug;15(8):1781-91. doi: 10.1158/1535-7163.MCT-15-0945. Epub 2016 Jul 13. Review. PubMed PMID: 27413114.
2. Stankovic T, Skowronska A. The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia. Leuk Lymphoma. 2014 Jun;55(6):1227-39. doi: 10.3109/10428194.2013.829919. Epub 2013 Sep 12. Review. PubMed PMID: 23906020.
3. Hernández JÁ, Hernández-Sánchez M, Rodríguez-Vicente AE, Grossmann V, Collado R, Heras C, Puiggros A, Martín AÁ, Puig N, Benito R, Robledo C, Delgado J, González T, Queizán JA, Galende J, de la Fuente I, Martín-Núñez G, Alonso JM, Abrisqueta P, Luño E, Marugán I, González-Gascón I, Bosch F, Kohlmann A, González M, Espinet B, Hernández-Rivas JM; Grupo Cooperativo Español de Citogenética Hematológica (GCECGH) and Grupo Español de Leucemia Linfática Crónica (GELLC). A Low Frequency of Losses in 11q Chromosome Is Associated with Better Outcome and Lower Rate of Genomic Mutations in Patients with Chronic Lymphocytic Leukemia. PLoS One. 2015 Dec 2;10(11):e0143073. doi: 10.1371/journal.pone.0143073. eCollection 2015. PubMed PMID: 26630574; PubMed Central PMCID: PMC4667902.

Další publikace

Příspěvky ve sborníku
A Comparison of Two Standardized Quantitative RT-PCRs with CE IVD Kit for Digital PCR in CML Patients with Different Level of BCR-ABL1 Transcripts Folta A, Jurcek T, **Kubesova B**, Mayer J and Jeziskova I. 61th ASH Annual Meeting and Exposition, Orlando, USA, Blood (2019) 134 (Supplement_1): 1646 Higher Rates of Molecular Response to Peg-IFNa in *JAK2*V617F Vs. Calr Mutant MPN Patients Are Due to JAK1-Mediated STAT1 Activation and Autoregulation Czech J, Cordua S, Weinbergerova B, Han L, Schubert C, Brümmendorf TH, Mayer J, Racil Z, **Kubesova B**, Knudsen TA, Sørensen A, Holmstrøm M, Kjær L, Skov V, Larsen, TS, Hasselbalch HC, Chatain N, and Koschmieder S. 59th ASH Annual Meeting and Exposition, Atlanta, USA, Blood (2017) 130 (Supplement 1): 4194 Low-Burden *TP53* Mutations Occur in Chronic Phase of Myeloproliferative Neoplasms Regardless of Hydroxyurea Administration, Disease Type, and *JAK2* Status **Kubesova B**, Pavlova S, Malcikova J, Kabathova J, Radova L, Tom N, Tichy B, Plevova K, Kantorova B, Fiedorova K, Kissova J, Gisslinger B, Gisslinger H, Mayer J, Kralovics R, Pospisilova S, Doubek M. 58th ASH Annual Meeting and Exposition, San Diego, USA, Blood (2016) 128 (22): 4284 Whole Exome Sequencing Identifies Novel *MPL* and *JAK2* Mutations in Triple Negative Myeloproliferative Neoplasms (oral presentation) Milosevic Feenstra JD, Nivarthi H, Gisslinger H, Leroy E, Rumi E, Chachoua I, Bagienski K, **Kubesova B**, Pietra D, Bettina Gisslinger B, Jäger R, Chen D, Berg T, Schalling M, Schuster M, Bock C, Constantinescu SN, Cazzola M, Robert Kralovics R. 57th ASH Annual Meeting and Exposition, Orlando, USA, Blood (2015) 126 (23): 606 ATM inactivation disturbs ATM-p53 pathway in response to DNA damage induced by doxorubicin but not fludarabine in CLL cells Navrkalova V, Sebejova L, **Kubesova B**, Doubek M, Mayer J, Pospisilova S, Trbusek M. 18th Congress of the European Hematology Association in Haematologica, Stockholm, Sweden; Haematologica Jun 2013, 98 (supplement 1) 1-768 Defects of ATM gene involving mutation lead to complete elimination of ATM function in chronic lymphocytic leukemia Navrkalova V, Sebejova L, Zemanova J, Kmínkova J, **Kubesova B**, Doubek M, Brychtova Y, Smardova J, Mayer J, Pospisilova S, Trbusek M. 54th ASH Annual Meeting and Exposition, Atlanta, USA; Blood (2012) 120 (21): 3902 Mutation status of ATM gene in CLL patients harboring deletion 11Q or *TP53* defect Navrkalova V, Sebejova L, Zemanova J, Kmínkova J, **Kubesova B**, Doubek M, Brychtova Y, Mayer J, Pospisilova S, Trbusek M. 17th Congress of the European Hematology Association, Amsterdam, Kingdom of the Netherlands; Haematologica Jun 2012, 97 (supplement 1)
Jiné
Sada pro detekci přítomnosti mutací v genu ATM u pacientů s CLL (výsledek s právní ochranou) Trbusek M, Jaskova Z, **Kubesova B**, Navrkalova V, Sebejova L, Plevova K. Kit for detecting the presence of mutations in the ATM gene in patients with chronic lymphocytic leukemia through a functional assay, 2017

……
datum a podpis uchazeče